About 100 reports

Acne Partnering 2010-2015

100 pages • By Currentpartnering

The Acne Partnering 2010-2015 report provides understanding and access to the acne partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in acne partnering dealsTop acne deals by valueDeals listed by company A-Z, industry sector, stage of development, technology type The Acne...

636 795 509
Mar 2015

Dermatitis Partnering 2010-2015

100 pages • By Currentpartnering

The Dermatitis Partnering 2010-2015 report provides understanding and access to the dermatitis partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in dermatitis partnering dealsTop dermatitis deals by valueDeals listed by company A-Z, industry sector, stage of development, technology...

636 795 509
Mar 2015

Actinic (Solar) Keratosis - Pipeline Review, H1 2015

96 pages • By Global Markets Direct

Actinic (Solar) Keratosis - Pipeline Review, H1 2015SummaryGlobal Markets Direct’s, ‘Actinic (Solar) Keratosis - Pipeline Review, H1 2015’, provides an overview of the Actinic (Solar) Keratosis’s therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Actinic (Solar)...

1 600 2 000 1 280
Feb 2015

Keloids - Pipeline Review, H1 2015

55 pages • By Global Markets Direct

Keloids - Pipeline Review, H1 2015SummaryGlobal Markets Direct’s, ‘Keloids - Pipeline Review, H1 2015’, provides an overview of the Keloids’s therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Keloids, complete with comparative analysis at various stages, therapeutics...

1 600 2 000 1 280
Feb 2015

Pemphigus - Pipeline Review, H1 2015

68 pages • By Global Markets Direct

Pemphigus - Pipeline Review, H1 2015SummaryGlobal Markets Direct’s, ‘Pemphigus - Pipeline Review, H1 2015’, provides an overview of the Pemphigus’s therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Pemphigus, complete with comparative analysis at various stages,...

1 600 2 000 1 280
Feb 2015

Ego Pharmaceuticals Pty Ltd - Strategic SWOT Analysis Review

18 pages • By Global Data

Ego Pharmaceuticals Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.This up-to-the-minute...

100 125 80
Feb 2015

Lipodystrophy - Pipeline Review, H1 2015

53 pages • By Global Markets Direct

Lipodystrophy - Pipeline Review, H1 2015SummaryGlobal Markets Direct’s, ‘Lipodystrophy - Pipeline Review, H1 2015’, provides an overview of the Lipodystrophy’s therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Lipodystrophy, complete with comparative analysis...

1 600 2 000 1 280
Feb 2015

Hyper Pigmentation - Pipeline Review, H1 2015

32 pages • By Global Markets Direct

Hyper Pigmentation - Pipeline Review, H1 2015SummaryGlobal Markets Direct’s, ‘Hyper Pigmentation - Pipeline Review, H1 2015’, provides an overview of the Hyper Pigmentation’s therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Hyper Pigmentation, complete with...

1 600 2 000 1 280
Feb 2015

The US Market for Rx to OTC Switches, 7th Edition

200 pages • By Kalorama Information

Over the past 38 years the U.S. Rx-to-OTC market has grown into a $7.8 billion market. This has mainly been due to factors such as patent expirations, increasing competitiveness with the pharmaceutical environment, brand re-invention, consumer demand, and cost containment strategies. The U.S. market for Rx-to-OTC Switches encompasses a wide...

3 196 3 995 2 557
Feb 2015

Acne Vulgaris-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Acne Vulgaris-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Acne Vulgaris. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III...

1 600 2 000 1 280
Feb 2015

Actinic (Solar) Keratosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Actinic (Solar) Keratosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Actinic (Solar) Keratosis. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for...

1 600 2 000 1 280
Feb 2015

Atopic Dermatitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Atopic Dermatitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Atopic Dermatitis. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and...

1 600 2 000 1 280
Feb 2015

Cellulitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Cellulitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Cellulitis. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline...

1 600 2 000 1 280
Feb 2015

Lichen Simplex Chronicus (Neurodermatitis)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Lichen Simplex Chronicus (Neurodermatitis)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Lichen Simplex Chronicus (Neurodermatitis). A key objective of DelveInsight’s report is to establish the understanding...

1 600 2 000 1 280
Feb 2015

Plaque Psoriasis (Psoriasis Vulgaris)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Plaque Psoriasis (Psoriasis Vulgaris)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Plaque Psoriasis (Psoriasis Vulgaris). A key objective of DelveInsight’s report is to establish the understanding...

1 600 2 000 1 280
Feb 2015

Acute Cutaneous Lupus Erythematosus (ACLE)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Acute Cutaneous Lupus Erythematosus (ACLE)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Acute Cutaneous Lupus Erythematosus (ACLE). A key objective of DelveInsight’s report is to establish the understanding...

1 600 2 000 1 280
Feb 2015

Angioedema-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Angioedema-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Angioedema. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline...

1 600 2 000 1 280
Feb 2015

Chronic Urticaria Or Hives-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Chronic Urticaria Or Hives-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Chronic Urticaria Or Hives. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers...

1 600 2 000 1 280
Feb 2015

Chronic Plaque Psoriasis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Chronic Plaque Psoriasis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Chronic Plaque Psoriasis. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for...

1 600 2 000 1 280
Feb 2015

Contact Dermatitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Contact Dermatitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Contact Dermatitis. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and...

1 600 2 000 1 280
Feb 2015

Dermatitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Dermatitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Dermatitis. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline...

1 600 2 000 1 280
Feb 2015

Eczema-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Eczema-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Eczema. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs...

1 600 2 000 1 280
Feb 2015

Genital Warts (Condylomata Acuminata)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Genital Warts (Condylomata Acuminata)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Genital Warts (Condylomata Acuminata). A key objective of DelveInsight’s report is to establish the understanding...

1 600 2 000 1 280
Feb 2015

Hereditary Angioedema (HAE)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Hereditary Angioedema (HAE)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Hereditary Angioedema (HAE). A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers...

1 600 2 000 1 280
Feb 2015

Ichthyosis Vulgaris-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Ichthyosis Vulgaris-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Ichthyosis Vulgaris. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed...

1 600 2 000 1 280
Feb 2015

Onychomycosis (Tinea Unguium)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Onychomycosis (Tinea Unguium)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Onychomycosis (Tinea Unguium). A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers...

1 600 2 000 1 280
Feb 2015

Pruritus-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Pruritus-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Pruritus. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline...

1 600 2 000 1 280
Feb 2015

Xerosis (Dry Skin)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

100 pages • By Delve Insight

DelveInsight’s, “Xerosis (Dry Skin)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Xerosis (Dry Skin). A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and...

1 600 2 000 1 280
Feb 2015

2015 Market Research Report on Global Acne Medication Industry

169 pages • By QY Research Group

Summary2015 Market Research Report on Global Acne Medication Industry is a professional and deep research report in this field. For overview analysis, the report introduces Acne Medication basic information including definition, classification, application, industry chain structure, industry overview, policy analysis,...

2 080 2 600 1 664
Feb 2015

Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2015

139 pages • By Global Markets Direct

Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2015SummaryGlobal Markets Direct’s, ‘Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2015’, provides an overview of the Systemic Sclerosis (Scleroderma)’s therapeutic pipeline.This report provides comprehensive information on the therapeutic development...

1 600 2 000 1 280
Jan 2015